Towards developing new strategies to reduce the adverse side-effects of nonsteroidal anti-inflammatory drugs

Clinical and Experimental Nephrology

Volumn 16, Issue 1, 2012, Pages 25-29

  Kawada, Noritaka ^a   Moriyama, Toshiki ^b   Kitamura, Harumi ^a   Yamamoto, Ryohei ^a   Furumatsu, Yoshiyuki ^a   Matsui, Isao ^a   Takabatake, Yoshitsugu ^a   Nagasawa, Yasuyuki ^a   Imai, Enyu ^c   Wilcox, Christopher S ^d   Rakugi, Hiromi ^a   Isaka, Yoshitaka ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d GEORGETOWN UNIVERSITY   (United States)

Author keywords

Analgesic; Antipyretic; COX 1; COX 2; EP; PGE 2

Indexed keywords

AQUAPORIN 2; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTACYCLIN; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E1; PROSTAGLANDIN E3; THROMBOXANE A2; VANILLOID RECEPTOR 1; VASOPRESSIN V2 RECEPTOR;

ADVERSE DRUG REACTION; ANALGESIC ACTIVITY; ANTIPYRETIC ACTIVITY; BLOOD PRESSURE REGULATION; BLOOD VESSEL TONE; CARDIOVASCULAR DISEASE; DIURESIS; EDEMA; HUMAN; HYPERTENSION; KIDNEY DYSFUNCTION; KIDNEY TUBULE; LUNG EMBOLISM; NATRIURESIS; NONHUMAN; PROSTAGLANDIN RELEASE; REVIEW; SODIUM EXCRETION; STOMACH MUCOSA LESION; VEIN THROMBOSIS;

ANALGESICS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIPYRETICS; BLOOD PRESSURE; CYCLOOXYGENASE 2 INHIBITORS; FEVER; HUMANS; INFLAMMATION; NATRIURESIS; PAIN; RECEPTORS, PROSTAGLANDIN E; RECEPTORS, PROSTAGLANDIN E, EP2 SUBTYPE; RECEPTORS, PROSTAGLANDIN E, EP4 SUBTYPE;

EID: 84858277636     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-011-0492-3     Document Type: Review

References (42)

1. DeWitt DL, Smith WL. Primary structure of prostaglandin G/H synthase from sheep vesicular gland determined from the complementary DNA sequence. Proc Natl Acad Sci USA. 1988;85:1412-6.
2. Smith WL, Dewitt DL. Prostaglandin endoperoxide H synthases- 1 and -2. Adv Immunol. 1996;62:167-215.
3. Wilcox CS. Nitric oxide synthase and cyclooxygenase in the kidney. In: Ruge MS, Patterson C, editors. Principles of molecular medicine. 2nd ed. Totowa: Hunana Press Inc; 2006. p. 606-12.
4. Farkouh ME, Greenberg BP. An evidence-based review of the cardiovascular risks of nonsteroidal anti-inflammatory drugs. Am J Cardiol. 2009;103:1227-37.
5. Blatteis CM. The onset of fever: new insights into its mechanism. Prog Brain Res. 2007;162:3-14. (Pubitemid 47080944)
6. Ushikubi F, Segi E, Sugimoto Y, Murata T, Matsuoka T, Kobayashi T, Hizaki H, Tuboi K, Katsuyama M, Ichikawa A, Tanaka T, Yoshida N, Narumiya S. Impaired febrile response in mice lacking the prostaglandin E receptor subtype EP3. Nature. 1998;395:281-4. (Pubitemid 28447553)
7. 2 receptor subtype in the rat brain: relationship to sites of interleukin-1-induced cellular responsiveness. J Comp Neurol. 2000;428:5-20.
8. 2 within specific nuclei of the brain in response to circulating interleukin-1beta. J Neurochem. 2000;74:2134-45.
9. 2 as a mediator of fever: the role of prostaglandin E (EP) receptors. Front Biosci. 2004;9:3046-57.
10. 2 produced by hematopoietic prostaglandin D synthase contributes to LPS-induced fever. J Physiol Pharmacol. 2009;60:145-50.
11. 1 and IP reveals peripheral nociceptive mechanism of prostaglandins. Mol Pain. 2005;1:3.
12. Reinold H, Ahmadi S, Depner UB, Layh B, Heindl C, Hamza M, Pahl A, Brune K, Narumiya S, Müller U, Zeilhofer HU. Spinal inflammatory hyperalgesia is mediated by prostaglandin E receptors of the EP2 subtype. J Clin Invest. 2005;115:673-9. (Pubitemid 40322241)
13. 3 in endotoxin-induced enhancement of pain perception. Biochem Pharmacol. 2001;62:157-60.
14. Lai LH, Chan FK. Nonsteroid anti-inflammatory drug-induced gastroduodenal injury. Curr Opin Gastroenterol. 2009;25:544-8.
15. Harirforoosh S, Jamali F. Renal adverse effects of nonsteroidal anti-inflammatory drugs. Expert Opin Drug Saf. 2009;8:669-81.
16. Gluais P, Lonchampt M, Morrow JD, Vanhoutte PM, Feletou M. Acetylcholine-induced endothelium-dependent contractions in the SHR aorta: the Janus face of prostacyclin. Br J Pharmacol. 2005;146:834-45. (Pubitemid 41622250)
17. 2) induces coronary vasodilatation in anaesthetised dogs. Cardiovasc Res. 1978;12:720-30.
18. 2 in the aorta of Wistar Kyoto rats and spontaneously hypertensive rats. Cardiovasc Res. 2008;78:130-8.
19. Coleman RA, Smith WL, Narumiya S. International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol Rev. 1994;46:205-29. (Pubitemid 24185151)
20. Sugimoto Y, Narumiya S. Prostaglandin E receptors. J Biol Chem. 1994;282:11613-7.
21. Harris RC, Zhang MZ, Cheng HF. Cyclooxygenase-2 and the renal renin-angiotensin system. Acta Physiol Scand. 2004;181: 543-7. (Pubitemid 39078853)
22. Friis UG, Stubbe J, Uhrenholt TR, Svenningsen P, Nüsing RM, Skøtt O, Jensen BL. Prostaglandin E2 EP2 and EP4 receptor activation mediates cAMP-dependent hyperpolarization and exocytosis of renin in juxtaglomerular cells. Am J Physiol. 2005;289:F989-97. (Pubitemid 41447053)
23. Nielsen S, Kwon TH, Christensen BM, Promeneur D, Frøkiær J, Marples D. Physiology and pathophysiology of renal aquaporins. J Am Soc Nephrol. 1999;10:647-63. (Pubitemid 29117647)
24. Melvin BF. Development of water transport in the collecting duct. Am J Physiol. 2004;287:F1093-101.
25. 2 receptor agonist alleviates disease in a new mouse model of X-linked nephrogenic diabetes insipidus. J Clin Invest. 2009;119:3115-26.
26. Seyberth HW, Königer SJ, Rascher W, Kühl PG, Schweer H. Role of prostaglandins in hyperprostaglandin E syndrome and in selected renal tubular disorders. Pediatr Nephrol. 1987;1:491-7. (Pubitemid 18016650)
27. 2 receptor. Am J Physiol. 2008;295:F818-25.
28. 4 receptor in furosemide-induced salt-losing tubulopathy: a model for hyperprostaglandin E syndrome/antenatal Bartter syndrome. J Am Soc Nephrol. 2005;16:2354-62.
29. Cipollone F, Prontera C, Pini B, Marini M, Fazia M, De Cesare D, Iezzi A, Ucchino S, Boccoli G, Saba V, Chiarelli F, Cuccurullo F, Mezzetti A. Overexpression of functionally coupled cyclooxygenase-2 and prostaglandin E synthase in symptomatic atherosclerotic plaques as a basis of prostaglandin E2-dependent plaque instability. Circulation. 2001;104:921-7. (Pubitemid 32778044)
30. Whelton A, Fort JG, Puma JA, Normandin D, Bello AE, Verburg KM, SUCCESS VI Study Group. Cyclooxygenase-2-specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am J Ther. 2001;8:85-95. (Pubitemid 33753522)
31. Whelton A, White WB, Bello AE, Puma JA, Fort JG, SUCCESSVII Investigators. Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis. Am J Cardiol. 2002;90:959-63. (Pubitemid 35232619)
32. Harris RC, McKanna JA, Akai Y, Jacobson HR, Dubois RN, Breyer MD. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J Clin Invest. 1994;94:2504-10. (Pubitemid 24379628)
33. Khan KN, Venturini CM, Bunch RT, Brassard JA, Koki AT, Morris DL, Trump BF, Maziasz TJ, Alden CL. Interspecies differences in renal localization of cyclooxygenase isoforms: implications in nonsteroidal antiinflammatory drug-related nephrotoxicity. Toxicol Pathol. 1998;26:612-20.
34. Kawada N, Solis G, Ivey N, Connors S, Dennehy K, Modlinger P, Hamel R, Kawada JT, Imai E, Langenbach R, Welch WJ, Wilcox CS. Cyclooxygenase-1 deficient mice have high sleep-to-awake ratios and renal vasoconstriction. Hypertension. 2005;45:1131-8.
35. Hetu PO, Riendeau D. Cyclo-oxygenase-2 contributes to constitutive prostanoid production in rat kidney and brain. Biochem J. 2005;391:561-6. (Pubitemid 41634781)
36. Cheng Y, Wang M, Yu Y, Lawson J, Funk CD, Fitzgerald GA. Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function. J Clin Invest. 2006;116:1391-9.
37. McAdam BF, Mardini IA, Habib A, Burke A, Lawson JA, Kapoor S, FitzGerald GA. Effect of regulated expression of human cyclooxygenase isoforms on eicosanoid and isoeicosanoid production in inflammation. J Clin Invest. 2000;105:1473-82. (Pubitemid 30322413)
38. Brown JR, DuBois RN. COX-2: a molecular target for colorectal cancer prevention. J Clin Oncol. 2005;23:2840-55. (Pubitemid 46179475)
39. Kennedy CR, Zhang Y, Brandon S, Guan Y, Coffee K, Funk CD, Magnuson MA, Oates JA, Breyer MD, Breyer RM. Salt-sensitive hypertension and reduced fertility in mice lacking the prostaglandin EP2 receptor. Nat Med. 1999;5:217-20. (Pubitemid 29068530)
40. 2 in acute and chronic kidney failure. Kidney Int. 2006;70:1099-106.
41. Takemoto F, Cohen HT, Satoh T, Katz AI. Dopamine inhibits Na/K-ATPase in single tubules and cultured cells from distal nephron. Pflugers Arch. 1992;421:302-6.
42. + transport by soluble adenylyl cyclase in kidney collecting duct cells. J Biol Chem. 2009;284:5774-83.